- Common shares of Telo Genomics (TELO) have commenced trading on the OTCQB under the symbol TDSGF
- Telo Genomics’ common shares will continue to trade on the TSXV under the symbol TELO
- Trading on the OTCQB provides U.S. investors access to the company’s shares
- Telo Genomics is a biotech company pioneering a telomere platform applicable to liquid biopsies and related technologies in oncology and neurological diseases
- Telo Genomics Corp. (TELO) is down 3.13 per cent on the day, trading at C$0.31 per share at 1:45 pm EST
Common shares of Telo Genomics (TELO) have commenced trading on the OTCQB under the symbol TDSGF.
Telo Genomics’ common shares will continue to trade on the TSXV under the symbol TELO.
The OTCQB is recognized by the Securities and Exchange Commission as an established public market providing public information for analysis and value of securities.
Christopher Ross, Telo Genomics’ CFO commented on the uplisting.
“We are pleased to have uplisted and initiated the quoting of our common shares on the OTCQB. This is an important step that increases access to our shares to a wider range of institutional and retail investors in the United States.”
“This is appropriate because our initial market is targeting unmet diagnostic and prognostic needs across the spectrum of multiple myeloma, a deadly form of blood cancer, in Canada and the United States,” he added.
Telo Genomics is a biotech company pioneering a telomere platform applicable to liquid biopsies and related technologies in oncology and neurological diseases.
Telo Genomics Corp. (TELO) is down 3.13 per cent on the day, trading at C$0.31 per share at 1:45 pm EST.
